The FDA on June 27, 2019 approved DARZALEX® in combination with REVLIMID® (Lenalidomide) and Dexamethasone for patients with newly diagnosed Multiple Myeloma who are ineligible for Autologous Stem Cell Transplant. DARZALEX® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
